Immunoexpression and clinical significance of the PTEN and MLH1 proteins in endometrial carcinomas

Polish Journal of Pathology

Volumn 61, Issue 4, 2010, Pages 185-191

  Bakiewicz, Anna ^a   Michalak, Jacek ^a   Sporny, Stanislaw ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Endometrial carcinoma; Microsatellite instability; MLH1; MMAC1; PTEN

Indexed keywords

MLH1 PROTEIN, HUMAN; NUCLEAR PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PTEN PROTEIN, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TUMOR MARKER;

ADENOCARCINOMA; ARTICLE; CANCER INVASION; CELL NUCLEUS; COLLOID CARCINOMA; CYSTADENOCARCINOMA; ENDOMETRIOID CARCINOMA; ENDOMETRIUM TUMOR; FEMALE; HUMAN; METABOLISM; MORTALITY; PATHOLOGY; POLAND; SURVIVAL RATE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOCARCINOMA; ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; CARCINOMA, ENDOMETRIOID; CELL NUCLEUS; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; NEOPLASM INVASIVENESS; NUCLEAR PROTEINS; POLAND; PTEN PHOSPHOHYDROLASE; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 79953322899     PISSN: 12339687     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Amant F, Moerman P, Neven P, et al. Endometrial cancer. Lancet 2005; 366: 491-505.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global Cancer Statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
3. Emons G, Fleckenstein G, Hinney B, et al. Hormonal interactions in endometrial cancer. Endocr Relat Cancer 2000; 7: 227-242.
4. Ryan AJ, Susil B, Jobling TW, Oehler MK. Endometrial cancer. Cell Tissue Res 2005; 322: 53-61.
5. Oehler MK, Brand A, Wain GV. Molecular genetics and endometrial cancer. J Br Menopause Soc 2003; 9: 27-31.
6. Hecht JL and Mutter GL. Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol 2006; 24: 4783-4791.
7. Li DM, Sun H. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res 1997; 57: 2124-2129.
8. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275: 1943-1947.
9. Wu X, Senechal K, Neshat MS, et al. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci U S A 1998; 95: 15587-15591.
10. Gu J, Tamura M, Yamada KM. Tumor suppressor PTEN inhibits integrin-and growth factor-mediated mitogen-activated protein (MAP) kinase signaling pathways. J Cell Biol 1998; 143: 1375-1383.
11. Tamura M, Gu J, Takino T, Yamada KM. Tumor suppressor PTEN inhibition of cell invasion, migration, and growth: differential involvement of focal adhesion kinase and p130Cas. Cancer Res 1999; 59: 442-449.
12. Mutter G. PTEN, a protean tumor suppressor. Am J Pathol 2001; 158: 1895-1898.
13. Chu EC, Tarnawski AS. PTEN regulatory functions in tumor suppression and cell biology. Med Sci Monit 2004; 10: 235-241.
14. Hamada K, Sasaki T, Koni PA, et al. The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis. Genes Dev 2005; 19: 2054-2065.
15. Website: MLH1 (human mutL homolog 1); http://www.atlasgeneticsoncology.org/Genes/MLH1ID149ch3p21.html.
16. Moslein G, Tester DJ, Lindor NM, et al. Microsatellite instability and mutation analysis of hMSH2 and hMLH1 in patients with sporadic, familial and hereditary colorectal cancer. Hum Mol Genet 1996; 5: 1245-1252.
17. Simpson AJ. The natural somatic mutation frequency and human carcinogenesis. Adv Cancer Res 1997; 71: 209-240.
18. Eng C. PTEN: one gene, many syndromes. Hum Mutat 2003; 22: 183-198.
19. Blumenthal GM, Dennis PA. PTEN hamartoma tumor syndromes. Eur J Hum Genet 2008; 16: 1289-1300.
20. Salvesen HB, Stefansson I, Kalvenes MB, et al. Loss of PTEN expression is associated with metastatic disease in patients with endometrial carcinoma. Cancer 2002; 94: 2185-2191.
21. Depowski PL, Rosenthal SI, Ross JS. Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Mod Pathol 2001; 14: 672-676.
22. Mutter GL, Lin MC, Fitzgerald JT, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000; 92: 924-930.
23. Eshelman J, Markowitz S. Microsatellite instability in inherited and sporadic neoplasms. Curr Opin Oncol 1995; 7: 83-89.
24. Modica I, Soslow RA, Black D, et al. Utility of immunohistochemistry in predicting microsatellite instability in endometrial carcinoma. Am J Surg Pathol 2007; 31: 744-751.
25. Hardisson D, Moreno-Bueno G, Sánchez L, et al. Tissue microarray immunohistochemical expression analysis of mismatch repair (hMLH1 and hMSH2 genes) in endometrial carcinoma and atypical endometrial hyperplasia: relationship with microsatellite instability. Mod Pathol 2003; 16: 1148-1158.
26. Arabi H, Guan H, Kumar S, et al. Impact of microsatellite instability (MSI) on survival in high grade endometrial carcinoma. Gynecol Oncol 2009; 113: 153-158.
27. Kobayashi K, Sagae S, Kudo R, et al. Microsatellite instability in endometrial carcinomas: frequent replication errors in tumors of early onset and/or of poorly differentiated type. Genes Chromosom Cancer 1995; 14: 128-132.
28. Caduff RF, Johnston CM, Svoboda-Newman SM, et al. Clinical and pathological significance of microsatellite instability in sporadic endometrial carcinoma. Am J Pathol 1996; 148: 1671-1678.
29. Matias-Guid X, Catasus L, Bussaglia E, et al. Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol 2001; 32: 569-577.